Abbott Laboratories (NYSE:ABT) Given New $140.00 Price Target at BTIG Research

Abbott Laboratories (NYSE:ABT) had its price objective reduced by investment analysts at BTIG Research from $145.00 to $140.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the healthcare product maker’s stock. BTIG Research’s target price would suggest a potential upside of 29.03% from the company’s current price.

A number of other brokerages have also recently weighed in on ABT. Weiss Ratings restated a “buy (b-)” rating on shares of Abbott Laboratories in a research note on Monday, December 29th. Evercore ISI raised their target price on shares of Abbott Laboratories from $142.00 to $144.00 and gave the stock an “outperform” rating in a report on Monday, January 5th. Mizuho boosted their target price on Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, October 14th. Sanford C. Bernstein increased their price target on shares of Abbott Laboratories from $150.00 to $154.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. Finally, Benchmark started coverage on Abbott Laboratories in a report on Friday, October 10th. They set a “buy” rating and a $145.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $146.56.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $108.50 on Friday. The company has a market capitalization of $188.67 billion, a price-to-earnings ratio of 13.60, a price-to-earnings-growth ratio of 2.00 and a beta of 0.72. Abbott Laboratories has a 12-month low of $105.78 and a 12-month high of $141.23. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The firm’s fifty day moving average price is $125.23 and its 200 day moving average price is $128.54.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The business had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter last year, the company posted $1.34 earnings per share. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ABT. IMG Wealth Management Inc. grew its position in Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after purchasing an additional 167 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new stake in Abbott Laboratories during the 4th quarter valued at $27,000. Cloud Capital Management LLC acquired a new position in Abbott Laboratories in the 3rd quarter valued at about $29,000. Guerra Advisors Inc bought a new position in shares of Abbott Laboratories during the third quarter worth approximately $31,000. Finally, Anfield Capital Management LLC boosted its position in shares of Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Med‑tech strength and margin expansion: Abbott said its Devices/MedTech businesses performed well in Q4 and reported adjusted EPS growth of ~12%, which supports longer‑term earnings power. Abbott Reports Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: Analyst support and income profile: Many sell‑side analysts maintain buy/outperform ratings and above‑current price targets, and the company’s Dividend‑King status and buyback capacity are cited as reasons some investors view the recent pullback as a buying opportunity. Is Abbott’s January Pullback a Good Time to Buy?
• Neutral Sentiment: Q4 EPS matched consensus: Abbott reported adjusted EPS of $1.50, in line with estimates — a neutral datapoint that limits the positive surprise potential. Abbott (ABT) Matches Q4 Earnings Estimates
• Negative Sentiment: Revenue miss and segment weakness: Total Q4 revenue of $11.46B fell short of Street estimates (~$11.8B). Weakness in Diagnostics (volatile post‑COVID testing) and a ~9% decline in Nutrition weighed on top‑line growth, prompting investor concern. Abbott misses quarterly revenue estimates on weakness in diagnostics segment
• Negative Sentiment: Guidance disappointed modestly: Q1 EPS guidance (1.12–1.18) is below consensus (~1.20) and FY adjusted EPS range (5.55–5.80) leaves limited upside vs. Street forecasts, which amplified the sell‑off after results. Abbott Reports Fourth-Quarter and Full-Year 2025 Results
• Negative Sentiment: Regulatory/legal risk in India: Documents show scrutiny of an Abbott Healthcare (India) supply chain tied to alleged misuse of a codeine‑based cough syrup — a developing regulatory issue that adds uncertainty and headline risk. Abbott faces India scrutiny in cough syrup abuse investigation, documents show
• Negative Sentiment: Options flow and investor positioning: There was a large uptick in put buying (≈80.6k puts), indicating elevated bearish bets or hedging demand that can accelerate downside during news flows. (trade flow reported by market sources)

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.